Prograf®

DRUG4 trials

Sponsors

Astellas Pharma Inc, Hannover Medical School, Astellas Pharma Canada, Inc., Chiesi Farmaceutici S.p.A.

Conditions

End Stage Renal DiseaseHealthyKidney TransplantationLung Transplantation

Phase 1

A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

CompletedNCT01681134

Astellas Pharma Canada, Inc.Healthy

Start: 2012-07-31End: 2012-10-31Updated: 2012-11-08

Phase 3

Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation

TerminatedNCT00930241

Hannover Medical SchoolLung Transplantation

Start: 2009-07-31End: 2012-07-31Updated: 2018-08-22

Phase 4

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection

CompletedNCT00717470

Astellas Pharma IncKidney Transplantation

Start: 2008-05-14End: 2010-03-02Updated: 2024-11-01

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

CompletedNCT02432833

Chiesi Farmaceutici S.p.A.End Stage Renal Disease

Start: 2015-05-31End: 2017-01-24Updated: 2018-04-13

Related Papers

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe

Transplant International2022-03-2114 citations

Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials.

2017-11-019 citations

A randomized cross‐over comparison of short‐term exposure of once‐daily extended release tacrolimus and twice‐daily tacrolimus on renal function in healthy volunteers

Transplant International2014-08-2717 citations